Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1994-07-01
1997-01-14
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
514 12, 514 21, 514258, 530351, 544260, A61K 3820, A61K 4505, A61K 3820, A61K 31505
Patent
active
055936717
ABSTRACT:
The invention provides a method of attenuating lung capillary leak in a mammal by administering an effective amount of an antifolate, methotrexate.
REFERENCES:
J. P. Seigel, R. K. Puri, Interleukin-2 Toxicity--Journal of Clinical Oncology, vol. 9, No. 4 (Apr.), 1991 pp. 694-704.
John T. Vetto et al, Reduction of Toxicity of Interleukin-2 and Lumpholine-Activated Killer Cells in Hmans by the Administration of Corticosteroids--Journal of Clinical Oncology, vol. 5 No. 3 (Mar.), 1987 pp. 496-503.
M. Z. Papa et al, Effect of Corticosteroid on the Antitumor Activity of Lympholine-activated Killer Cells and Interleukin-2 in Mice--Cancer Research 46, 5618-5623, Nov. 1986.
D. R. Seeger et al, Analogs of Peroylutamic Acid. III. 4-Amino Derivatives--May 1949 4-Amino Derivatives of pteroylglutamic Acid pp. 1753-1758.
M. V. Freeman, The Fluormetric measurement of the Absorption, Distribution and Excretiion of Single Doses of 4-Amino-10-Methyl Pteroylglutamic Acid (Amethopterin) in man--Clinical Pharmacology and Experimental Therapeutics Section, national Cancer Institute pp. 154-162.
E. S. Henderson et al, The Metabolic Fate of Tritiated methotrexate II. Absorption and Excretion in Man pp. 1018-1024.
P. T. Condit, Studies of the Folic Acid Vitamins. II. The Acute Toxicity of Amethopterin in Man and Studies on the Folic Acid Vitamins, III. The Duration of the Effects of Folic Acid Antagonists in Man--American Cancer Society 1960 vol. 13 pp. 221-235.
P. T. Condit, et al, Renal Toxicity of Methotrexate--Oklahmoma Medical Research Foundation, Jun. 3, 1968 pp. 126-131.
K. B. Bischoff, et al, Preliminary Model for Methotrexate Pharmacokinetics--Research Articles vol. 59 No. 2 Feb. 1970 pp. 149-154.
K. B. Bischoff, et al, Methotrexate Pharmacokinetics--Journal of Pharmaceutical Sciences--pp. 1128-1133.
W. E. Evans, Methotrexate--pp. 518-548.
J. R. Bertino, Clinical use of methotrexate-With Emphasis on use of High Doses--Cancer Treatment reports, vol. 65, Supplement 1, 1981 pp. 131-135.
J. Jolivet, et al, Medical progress, The Pharmacology and Clinical Use of Methotrexate--The New England Journal of Medicine, Nov. 3, 1983, pp. 1094-1104.
A. Weinstein, Methotrexate: A Perspective on Its Use for Rheumatoid Arthritis, Journal of Rheumatology Supplement No. 12, 1985--pp. 1-2.
J. R. Ward, Historical Perspective on the Use of Methotrexate for the Treatment of Rheumatoid Arthritis, Journal of Rheumatology Supplement No. 12, 1985 pp. 3-6.
D. E. Trentham, The Immunopathogenesis of Rheumatoid Arthritis, Journal of Rheumatology Supplement No. 12, 1985, pp. 7-10.
D. E. Furst, Clinical Pharmacology of Very Low Dose Methotrexate or Use in Rheumatoid Arthritis, Journal of Rheumatology Supplement No. 12, pp. 11-14.
W. E. Evans, M. K. Christensen, Drug Interactions with methotrexate--Journal of Rheumatology Supplement No. 12, 1985, pp. 15-20.
R. F. Willkens, Short Term Efficacy of Methotrexate in the Treatment of Rheumatoid Arthritis--Journal of Rheumatology Supplement No. 12, 1985, pp. 21-24.
J. M. Kremer, Longterm Methotrexate Therapy in Rheumatoid Arthritis: A Review--Journal of Rheumatology Supplement No. 12, 1985 pp. 25-28.
K. G. Tolman, et al, Methotrexate and the Liver--Journal of Rheumatology Supplement No. 12, pp. 29-34.
M. E. Weinblatt, Toxicity of Low Dose Methotrexate in Rheumatoid Arthritis--Journal of Rheumatology Supplement No. 12, 1985, pp. 35-39.
J. R. Ward, Summary, Journal of Rheumatology Supplement No. 12, 1985, pp. 40-44.
M. Rosenstein, Extravasation of Intravascular Fluid Mediated by the Systemic Administration of recombinant Interleukin 2--The Journal of Immunology, vol. 137, 1735-1742, Sep. 1, 1966.
Package Insert, Methotrexate Tablets, Methotrexate Sodium and Methotrexate LPF* Sodium Parenteral, May 1988.
D. L. Fraker, et al, Passive Immunizatin Against Tumor necrosis Factor partially Abrogates Interleukin 2 Toxicity--The Journal of Experimental Medicine vol. 170 Sep. 1989 pp. 1015-1020.
M. Fleisher, Antifolate Analogs: mechanism of Action, Analytical methodology, and Clinical Efficacy--Therapeutic Drug Monitoring, 15 pp. 521-526 1993.
K. S. Antman, et al, Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression--The New England Journal of Medicine, vol. 319, No. 10, Sep. 1988, pp. 593-598.
S. J. Brandt, et al, Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Hematopoietic reconstitution After High-Dose Chemotherapy and Autologous Bone Marror Transplantation, The New England of medicine, vol. 318, No. 14, Apr. 1988, pp. 869-876.
Package Insert, Proleukin Aldesleukin for Injection, Nov. 1992.
Kerwar Suresh S.
Wick Michael M.
Achutamurthy Ponnathapura
American Cyanamid Company
Boswell, Jr. R. F.
Szatkowski T. G.
LandOfFree
Method of attenuating lung capillary leak in a mammal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of attenuating lung capillary leak in a mammal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of attenuating lung capillary leak in a mammal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1386125